SAGIMET BIOSCIENCES INC-A

SGMTNASDAQ

🏆 #2837 by market capEarnings Nov 16 · PreUS Equity

$9.32▼ $0.59 (−6.33%)

After hours · at close

🔔

Track SGMT

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 6.3%

7d▼ 15.8%

14d▼ 10.9%

30d▼ 11.7%

ytd▲ 57.4%

1y▲ 34.4%

🏦Market Cap

$576M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

Trading Snapshot

Day Range: $9.25 – $9.44
52-Week Range: $4.50 – $11.45
Volume: $2.87B
Avg Volume: $3.01B
Shares Outstanding: 61.8M
Next Earnings: Dec 9, 2026

Fundamentals Snapshot

Annual Revenue: $144M
Last Q Revenue: $34M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.28
Dividend Yield: —
Dilution (1yr): +1.0%

Why Investors Own SGMT

✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
✓Healthy economics — 33% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SAGIMET BIOSCIENCES INC-A

SGMT

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$57M▲ +4.5% YoY

Free Cash Flow

−$46M▲ +7.6% YoY

Shares Outstanding

32.5M▲ +1.0% YoY

Net Cash

$35M▼ −$41M YoY

StockOtter · stockotter.space

About SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

🦦